Recent Fed rate cut hints, pharmaceutical stock surge, Apple TV+ subscription increase
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 21 2025
0mins
Source: Yahoo Finance
Federal Reserve Update: Cleveland Fed President Beth Hammack stated she would not support cutting interest rates if the Fed were to meet tomorrow, amidst the annual symposium at Jackson Hole.
Pharmaceutical Stocks Surge: Pharmaceutical companies like Teva, Pfizer, and Eli Lilly saw stock increases after the US-EU trade deal revealed a more favorable 15% tariff on pharmaceutical goods, easing previous tariff concerns.
Walmart's Profit Miss: Walmart shares declined following the company's first profit miss in three years, although it did raise its sales guidance for the year.
Apple TV+ Price Increase: Apple announced a 30% increase in its Apple TV+ subscription price, raising it to $12.99 per month, effective immediately.
Analyst Views on TEVA
Wall Street analysts forecast TEVA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TEVA is 35.71 USD with a low forecast of 29.00 USD and a high forecast of 40.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
11 Analyst Rating
10 Buy
1 Hold
0 Sell
Strong Buy
Current: 31.660
Low
29.00
Averages
35.71
High
40.00
Current: 31.660
Low
29.00
Averages
35.71
High
40.00
About TEVA
Teva Pharmaceutical Industries Ltd is a Israeli-based pharmaceutical company. The Company operates through three segments: North America, Europe and International Markets. Each business segment manages entire product portfolio in its region, including generics, specialty and over-the-counter (OTC) products. In addition to these three segments, The Company has other activities, primarily the sale of active pharmaceutical ingredients (API) to third parties, certain contract manufacturing services and an out-licensing platform offering a portfolio of products to other pharmaceutical companies through its affiliate Medis.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
